세계의 인플루엔자 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Influenza Treatment Market is presumed to reach the market size of nearly USD 7.34 BN by 2030 from USD 6.13 BN in 2022 with a CAGR of 2.27% under the study period 2023 - 2030.

Influenza treatment primarily focuses on alleviating symptoms and preventing complications, as influenza, commonly known as the flu. It is caused by viruses, and antibiotics are ineffective against viral infections. Antiviral medications are frequently recommended to mitigate the intensity and duration of symptoms associated with influenza. These medications work by inhibiting the replication of the influenza virus in the body.

MARKET DYNAMICS

The influenza treatment market is driven by several key factors, including the seasonal nature of influenza, leading to a consistent demand during peak flu seasons. The increasing global population, especially in densely populated regions, contributes to the likelihood of flu outbreaks, fueling the market's growth. Ongoing research and development in antiviral medications and treatment methods play a pivotal role in addressing the need for innovative solutions, particularly in the face of emerging influenza strains and potential pandemics. Government initiatives and public health campaigns promoting flu vaccination contribute to shaping the market, emphasizing the importance of preventive measures. Awareness efforts focusing on early diagnosis and treatment also play a role in market expansion. The prevalence of chronic diseases, which elevate the risk of severe influenza complications, further drives the demand for effective treatments. Factors such as healthcare infrastructure, policies, and economic conditions can influence the market, and the continuous evolution of influenza viruses necessitates adaptable treatment strategies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of influenza treatment. The growth and trends of influenza treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the influenza treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

• Peramivir
• Zanamivir
• Baloxavir Marboxil
• Oseltamivir Phosphate
• Others

By Route Of Administration

• Oral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Influenza Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Influenza Treatment market include NATCO Pharma Limited, Novartis AG, F. Hoffmann-La Roche Ltd, BioCryst Pharmaceuticals, Inc., Sanofi, GSK plc., Viatris Inc. (MYLAN), Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company, Ltd., AstraZeneca. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . INFLUENZA TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Treatment
  • 3.7.2 Market Attractiveness Analysis By Route of Administration
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL INFLUENZA TREATMENT MARKET ANALYSIS BY TREATMENT

• 5.1 Overview by Treatment
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Treatment
• 5.4 Peramivir Historic and Forecast Sales by Regions
• 5.5 Zanamivir Historic and Forecast Sales by Regions
• 5.6 Baloxavir Marboxil Historic and Forecast Sales by Regions
• 5.7 Oseltamivir Phosphate Historic and Forecast Sales by Regions
• 5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL INFLUENZA TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1 Overview by Route of Administration
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Route of Administration
• 6.4 Oral Historic and Forecast Sales by Regions
• 6.5 Others Historic and Forecast Sales by Regions

7 . GLOBAL INFLUENZA TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1 Overview by Distribution Channel
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Distribution Channel
• 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL INFLUENZA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE INFLUENZA TREATMENT COMPANIES

• 9.1. Influenza Treatment Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF INFLUENZA TREATMENT INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. NATCO Pharma Limited
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Novartis AG
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. F. Hoffmann-La Roche Ltd
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. BioCryst Pharmaceuticals Inc.
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Sanofi
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. GSK plc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. Viatris Inc. (MYLAN)
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Teva Pharmaceutical Industries Ltd.
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Daiichi Sankyo Company Ltd.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. AstraZeneca
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies